Synthesis and benzodiazepine receptor (ω receptor) affinities of 3-substituted derivatives of pyrrolo[2,3-c]pyridine-5-carboxylate, a novel class of ω1 selective ligands

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 5, 1999, Pages 921-932

  Doisy, Xavier ^a   Dekhane, Mouloud ^a   Le Hyaric, Mireille ^a   Rousseau, Jean François ^a   Singh, Sunil K ^a   Tan, Suan ^b   Guilleminot, Valérie ^b   Schoemaker, Hans ^b   Sevrin, Mireille ^b   George, Pascal ^b   Potier, Pierre ^a   Dodd, Robert H ^a  

^a CNRS   (France)

^b SANOFI   (France)

Author keywords

Benzodiazepine receptor; Modeling; Pyrrolo 2,3 c pyridine 5 carboxylate; Selectivity; Synthesis

Indexed keywords

5 BENZYLOXY 4 METHOXYMETHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; BENZODIAZEPINE RECEPTOR; LIGAND; PARTIAL AGONIST; PYRROLO[3,2 C]PYRIDINE DERIVATIVE; RECEPTOR SUBTYPE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR MODEL; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BRAIN; CARBOLINES; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MODELS, MOLECULAR; PYRIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A;

EID: 0033135942     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00053-X     Document Type: Article

References (64)

1. Sternbach, L. H. J. Med. Chem. 1979, 22, 1.
2. For reviews, see: (a) Haefely, W.; Kyburz, E.; Gerecke, M.; Mohler, H. Advances in Drug Research; Testa, B., Ed.; Academic: London, 1985; Vol. 14, pp 165-322.
3. (b) Gardner, C. R.; Tully, W. R.; Hedgecock, C. J. R. Prog. Neurobiol. 1993, 40, 1.
4. (a) Stratten, W. P.; Barnes, C. D. Neuropharmacology 1971, 10, 685.
5. (b) Steiner, F. A.; Felix, D. Nature 1976, 260, 346.
6. (a) Squires, R. F.; Braestrup, C. Nature 1977, 266, 732.
7. (b) Möhler, H.; Okada, T. Science 1977, 198, 849.
8. (a) Tallman, J. F.; Thomas, J. W.; Gallager, D. W. Nature 1978, 274, 383.
9. (b) Gavish, M.; Snyder, S. H. Life Sci. 1980, 26, 579.
10. (c) Study, R. E.; Barker, J. L. Proc. Natl. Acad. Sci. USA 1981, 78, 7180.
11. Hunkeler, W.; Möhler, H.; Pieri, L.; Polc, P.; Bonetti, E. P.; Cumin, R.; Schaffner, R.; Haefely, W. Nature 1981, 290, 514.
12. Klepner, C. A.; Lippa, A. S.; Benson, D. I.; Sano, M. C.; Beer, B. Pharmacol. Biochem. Behav. 1979, 11, 457.
13. Yokoyama, N.; Ritter, B.; Neubert, A. D. J. Med. Chem. 1982, 25, 337.
14. (a) Braestrup, C.; Schmiechen, R.; Neef, G.; Nielsen, M.; Petersen, E. N. Science 1982, 216, 1241.
15. (b) Braestrup, C.; Nielsen, M.; Olsen, C. E. Proc. Natl. Acad. Sci. USA 1980, 77, 2288.
16. (c) Oakley, N. R.; Jones, B. J. Neuropharmacology 1982, 21, 587.
17. (d) Prado de Carvalho, L.; Grecksch, G.; Cavalheiro, E. A.; Dodd, R. H.; Chapouthier, G.; Rossier, J. Eur. J. Pharmacol. 1984, 103, 287.
18. (e) Prado de Carvalho, L.; Grecksch, G.; Chapouthier, G.; Rossier, J. Nature 1983, 301, 64.
19. (a) Venault, P.; Chapouthier, G.; Prado de Carvalho, L.; Simiand, J.; Morre, M.; Dodd, R. H.; Rossier, J. Nature, 1986, 321, 864.
20. (b) Raffalli-Sébille, M. J.; Chapouthier, G.; Venault, P.; Dodd, R. H. Pharmacol. Biochem. Behav. 1990, 35, 281.
21. (c) For a review of the memory-enhancing activities of β-carbolines, see: Dodd, R. H. Eur. Bull. Cog. Psychol. 1992, 12, 484.
22. (a) Nielsen, M.; Braestrup, C. Nature 1980, 286, 606.
23. (b) Olsen, R. W.; McCabe, R. T.; Wamsley, J. K. J. Chem. Neuroanat. 1990, 3, 59.
24. (c) Sieghart, W.; Schlerka, W. Eur. J. Pharmacol. 1991, 197, 103.
25. (a) Sieghart, W. Trends Pharmacol. Sci. 1989, 10, 407.
26. (b) Zezula, J.; Karall, S.; Dodd, R. H.; Sieghart, W. Eur. J. Pharmacol. 1995, 281, 93.
27. (c) Potier, M.-C.; Prado de Carvalho, L.; Dodd, R. H.; Besseliévre, R.; Rossier, J. Mol. Pharmacol. 1988, 34, 124.
28. (d) Mazière, M.; Hantraye, P.; Kajima, M.; Dodd, R. H.; Guibert, B.; Prenant, C.; Sastre, J.; Crouzel, M.; Comar, D.; Naquet, R. Life Sci. 1985, 36, 1609.
29. Nayeem, N.; Green, T. P.; Martin, I. L.; Barnard, E. A. J. Neurochem. 1994, 62, 815.
30. For reviews, see: (a) Lüddens, H.; Wisden, W. Trends Pharm. Sci. 1991, 12, 49.
31. (b) Sieghart, W. Pharmacol. Rev. 1995, 47, 181.
32. Pritchett, D. B.; Sontheimer, H.; Shivers, B. D.; Ymer, S.; Kattenmann, H.; Schofield, P. R.; Seeburg, P. H. Nature 1989, 338, 582.
33. (a) Von Blankenfeld, G.; Ymer, S.; Pritchett, D. B.; Sontheimer, H.; Ewert, M.; Seeburg, P. H.; Kettenmann, H. Neurosci. Lett. 1990, 115, 269.
34. (b) Kleingoor, C.; Ewert, M.; Von Blankenfeld, G.; Seeburg, P. H.; Kettenmann, H. Neurosci. Lett. 1991, 130, 169.
35. (c) Puia, G.; Vicini, S.; Seeburg, P. H.; Costa, E. Mol. Pharmacol. 1991, 39, 691.
36. (d) Wafford, K. A.; Whiting, P. J.; Kemp, J. A. Mol. Pharmacol. 1993, 43, 240.
37. (a) Maquire, P. A.; Davies, M. F.; Villar, H. O.; Loew, G. Eur. J. Pharmacol. 1992, 214, 85.
38. (b) Pritchett, D. B.; Lüddens, H.; Seeburg, P. H. Science 1989, 245, 1389.
39. (c) Tan, S.; Schoemaker, H. Can. J. Physiol. Pharmacol. 1994, 72, 448.
40. (a) Benavides, J.; Peny, B.; Scatton, B. Eur. J. Neuropsychopharmacol. 1991, 3, 398.
41. (b) Dennis, T.; Dubois, A.; Benavides, J.; Scatton, B. J. Pharmacol. Exp. Ther. 1988, 247, 309.
42. (c) Benavides, J.; Peny, B.; Durand, A.; Arbilla, S.; Scatton, B. J. Pharmacol. Exp. Ther. 1992, 263, 884.
43. (d) Pritchett, D. B.; Seeburg, P. H. J. Neurochem. 1990, 54, 1802.
44. Liu, R.; Hu, R. J.; Zhang, P.; Skolnick, P.; Cook, J. M. J. Med. Chem. 1996, 39, 1928.
45. (a) Dodd, R. H.; Ouannès, C.; Prado de Carvalho, L.; Valin, A.; Venault, P.; Chapouthier, G.; Rossier, J.; Potier, P. J. Med. Chem. 1985, 28, 824.
46. (b) Dodd, R. H.; Ouannès, C.; Potier, M.-C.; Prado de Carvalho, L.; Rossier, J.; Potier, P. J. Med. Chem. 1987, 30, 1248.
47. (c) Dorey, G.; Poissonnet, G.; Potier, M.-C.; Prado de Carvalho, L.; Venault, P.; Chapouthier, G.; Rossier, J.; Potier, P.; Dodd, R. H. J. Med. Chem. 1989, 32, 1799.
48. (d) Dorey, G.; Dubois, L.; Prado de Carvalho, L.; Potier, P.; Dodd, R. H. J. Med. Chem. 1995, 38, 189.
49. (a) Stephens, D. N.; Kehr, W.; Wachtel, H.; Schmiechen, R. Pharmacopsychiatry 1985, 18, 167.
50. (b) Hollinshead, S. P.; Trudell, M. L.; Skolnick, P.; Cook, J. M. J. Med. Chem. 1990, 33, 1062.
51. (c) Petersen, E. N.; Jensen, L. H.; Honoré, T.; Braestrup, C.; Kehr, W.; Stephens, D. N.; Wachtel, H.; Seidelman, D.; Schmiechen, R. Psychopharmacologia, 1984, 83, 240.
52. Zhang, W.; Koehler, K. F.; Zhang, P.; Cook, J. M. Drug Design Discovery 1995, 12, 193.
53. (a) Rousseau, J.-F.; Dodd, R. H. J. Org. Chem. 1998, 63, 2731.
54. (b) Dekhane, M.; Potier, P.; Dodd, R. H. Tetrahedron 1993, 49, 8139.
55. (c) Dodd, R. H.; Doisy, X.; Potier, P.; Potier, M.-C.; Rossier, J. Heterocycles 1989, 28, 1101.
56. Coker, J. N.; Mathre, O. B.; Todd, W. H. J. Org. Chem. 1963, 28, 589.
57. (a) Sonnet, P. E. J. Med. Chem. 1972, 15, 97.
58. (b) Loader, C. E.; Anderson, H. J. Tetrahedron 1969, 25, 3879.
59. Dekhane, M.; Dodd, R. H. Tetrahedron 1994, 50, 6299.
60. Olivier, A.; Sevrin, M.; Durant, F.; George, P. Bioorg. Med. Chem. Lett. 1997, 7, 2277.
61. Cox, E. D.; Diaz-Arauzo, H.; Huang, Q.; Reddy, M. S.; Ma, C.; Harris, B.; McKernan, R.; Skolnick, P.; Cook, J. M. J. Med. Chem. 1998, 41, 2537.
62. Schoemaker, H.; Claustre, Y.; Fage, D.; Rouquier, L.; Chergui, K.; Curet, O.; Oblin, A.; Gonon, F.; Carter, C.; Benavides, J.; Scatton, B. J. Pharmacol. Exp. Ther. 1997, 280, 83.
63. Braestrup, C.; Nielsen, M. Trends Neurosci. 1980, 3, 301.
64. Ruano, D.; Vizuete, M.; Cano, J.; Machado, A.; Vitorica, J. J. Neurochem. 1992, 58, 485.